Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bcp.12373 http://scihub22266oqcxt.onion/10.1111/bcp.12373 C4243903!4243903 !24606567     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24606567 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Br+J+Clin+Pharmacol 2014 ; 78 (3 ): 524-32 Nephropedia Template TP {{tp|p=24606567 |t=2014. Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours |pdf=|usr=}}{{24606567 }} gab.com Text Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours JO: Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=24606567 #FOAvip AIMS: The aim of this phase 1, single centre, open label study in four patients with solid tumours was to determine the absolute bioavailability of a 2?mg oral dose of trametinib. Trametinib is an orally bioavailable, reversible and selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity. METHODS: A microtracer study approach, in which a 5??g radiolabelled i.v. microdose of trametinib was given concomitantly with an unlabelled 2?mg oral tablet formulation, was used to recover i.v. and oral pharmacokinetic parameters, simultaneously. RESULTS: The least-squares mean (90% confidence interval) absolute bioavailability of trametinib (2?mg tablet) was 72.3% (50.0%, 104.6%). Median tmax after oral administration was 1.5?h and the geometric mean terminal half-life was 11?days. The geometric mean clearance and volume of distribution after i.v. administration were 3.21?l?h(-1) and 976?l, respectively, resulting in a terminal elimination half-life of 11?days. CONCLUSIONS: Trametinib absolute bioavailability was moderate to high, whereas first pass metabolism was low. Twit Text FOAVip Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours ????Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=24606567 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24606567 #FOAvip English Wikipedia <ref>{{Cite pmid|24606567 }}</ref> Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours #MMPMID24606567 Leonowens C ; Pendry C ; Bauman J ; Young GC ; Ho M ; Henriquez F ; Fang L ; Morrison RA ; Orford K ; Ouellet D Br J Clin Pharmacol 2014[Sep]; 78 (3 ): 524-32 PMID24606567 show ga AIMS: The aim of this phase 1, single centre, open label study in four patients with solid tumours was to determine the absolute bioavailability of a 2?mg oral dose of trametinib. Trametinib is an orally bioavailable, reversible and selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity. METHODS: A microtracer study approach, in which a 5??g radiolabelled i.v. microdose of trametinib was given concomitantly with an unlabelled 2?mg oral tablet formulation, was used to recover i.v. and oral pharmacokinetic parameters, simultaneously. RESULTS: The least-squares mean (90% confidence interval) absolute bioavailability of trametinib (2?mg tablet) was 72.3% (50.0%, 104.6%). Median tmax after oral administration was 1.5?h and the geometric mean terminal half-life was 11?days. The geometric mean clearance and volume of distribution after i.v. administration were 3.21?l?h(-1) and 976?l, respectively, resulting in a terminal elimination half-life of 11?days. CONCLUSIONS: Trametinib absolute bioavailability was moderate to high, whereas first pass metabolism was low. |Administration, Intravenous [MESH] |Administration, Oral [MESH] |Antineoplastic Agents/*administration & dosage/pharmacokinetics/therapeutic use [MESH] |Biological Availability [MESH] |Female [MESH] |Half-Life [MESH] |Humans [MESH] |MAP Kinase Kinase 1/antagonists & inhibitors [MESH] |MAP Kinase Kinase 2/antagonists & inhibitors [MESH] |Male [MESH] |Neoplasms/*drug therapy [MESH] |Protein Kinase Inhibitors/*administration & dosage/pharmacokinetics/therapeutic use [MESH] |Pyridones/*administration & dosage/pharmacokinetics/therapeutic use [MESH] |Pyrimidinones/*administration & dosage/pharmacokinetics/therapeutic use [MESH]Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK(epmc).pdf DeepDyve Pubget Overpricing